New data at american college of gastroenterology annual meeting show tissuecypher® provides actionable risk insights that influence clinical management and prompt risk-aligned intervention in barrett's esophagus

Friendswood, texas, oct. 26, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its tissuecypher® barrett's esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. the research will be presented in three posters at the american college of gastroenterology (acg) 2025 annual scientific meeting, taking place oct. 27–29, 2025, in phoenix, arizona, including one selected for a presidential poster award.
CSTL Ratings Summary
CSTL Quant Ranking